Multimorbidity and fluid biomarkers of Alzheimer's disease: a systematic review.

IF 3.6 3区医学 Q2 GERIATRICS & GERONTOLOGY

European Geriatric Medicine Pub Date : 2025-08-01 Epub Date: 2025-05-20 DOI:10.1007/s41999-025-01222-y

Martina Valletta, Marco Canevelli, Francesca Gasparini, Simona Buscarnera, Martina Salzillo, Federico Triolo, Amaia Calderón-Larrañaga, Alessandra Marengoni, Davide Liborio Vetrano, Giulia Grande

{"title":"Multimorbidity and fluid biomarkers of Alzheimer's disease: a systematic review.","authors":"Martina Valletta, Marco Canevelli, Francesca Gasparini, Simona Buscarnera, Martina Salzillo, Federico Triolo, Amaia Calderón-Larrañaga, Alessandra Marengoni, Davide Liborio Vetrano, Giulia Grande","doi":"10.1007/s41999-025-01222-y","DOIUrl":null,"url":null,"abstract":"Purpose: This systematic review aimed to summarize the evidence on the association between multimorbidity and fluid biomarkers of Alzheimer's disease (AD).Methods: We systematically searched PubMed, Web of Science, and Embase for studies investigating the association between multimorbidity-defined as the co-occurrence of multiple chronic conditions in the same individual-and levels of cerebrospinal fluid (CSF) or blood biomarkers of AD, focusing on the most established AD biomarkers (amyloid-beta, phosphorylated-tau, total-tau, neurofilament light chain, and glial fibrillary acidic protein). Studies were selected following PRISMA guidelines.Results: Out of 3,104 records, we identified 10 cross-sectional studies. Four studies assessed CSF biomarkers in dementia-free participants with mean age between 61.8 and 66.6 years, yielding mixed findings with no consistent association between multimorbidity and CSF biomarkers. Six studies focused on blood biomarkers in participants with mean age ranging from 66.5 to 76.4 years, five of which included individuals with dementia. Most of these studies reported an association between multimorbidity and elevated blood biomarker levels.Conclusions: This review suggests a significant association between multimorbidity and AD blood biomarkers in older populations, while the results on CSF are mixed and inconsistent. Further research is needed, particularly longitudinal studies assessing both CSF and blood biomarkers within the same populations.","PeriodicalId":49287,"journal":{"name":"European Geriatric Medicine","volume":" ","pages":"1121-1136"},"PeriodicalIF":3.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378289/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Geriatric Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s41999-025-01222-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This systematic review aimed to summarize the evidence on the association between multimorbidity and fluid biomarkers of Alzheimer's disease (AD).

Methods: We systematically searched PubMed, Web of Science, and Embase for studies investigating the association between multimorbidity-defined as the co-occurrence of multiple chronic conditions in the same individual-and levels of cerebrospinal fluid (CSF) or blood biomarkers of AD, focusing on the most established AD biomarkers (amyloid-beta, phosphorylated-tau, total-tau, neurofilament light chain, and glial fibrillary acidic protein). Studies were selected following PRISMA guidelines.

Results: Out of 3,104 records, we identified 10 cross-sectional studies. Four studies assessed CSF biomarkers in dementia-free participants with mean age between 61.8 and 66.6 years, yielding mixed findings with no consistent association between multimorbidity and CSF biomarkers. Six studies focused on blood biomarkers in participants with mean age ranging from 66.5 to 76.4 years, five of which included individuals with dementia. Most of these studies reported an association between multimorbidity and elevated blood biomarker levels.

Conclusions: This review suggests a significant association between multimorbidity and AD blood biomarkers in older populations, while the results on CSF are mixed and inconsistent. Further research is needed, particularly longitudinal studies assessing both CSF and blood biomarkers within the same populations.

Abstract Image

查看原文本刊更多论文

阿尔茨海默病的多发病和液体生物标志物：系统综述。

目的：本系统综述旨在总结阿尔茨海默病（AD）多发病与液体生物标志物之间的关联证据。方法：我们系统地检索了PubMed、Web of Science和Embase，以调查多重发病（定义为同一个体中多种慢性疾病的共同发生）与阿尔茨海默病脑脊液（CSF）或血液生物标志物水平之间的关系，重点关注最成熟的阿尔茨海默病生物标志物（淀粉样蛋白- β、磷酸化tau蛋白、总tau蛋白、神经丝轻链和胶质纤维酸性蛋白）。研究是根据PRISMA指南选择的。结果：在3104份记录中，我们确定了10份横断面研究。四项研究评估了平均年龄在61.8岁至66.6岁之间的无痴呆参与者的脑脊液生物标志物，结果好坏不一，多发性疾病与脑脊液生物标志物之间没有一致的关联。六项研究的重点是参与者的血液生物标志物，平均年龄在66.5至76.4岁之间，其中五项研究包括痴呆症患者。这些研究大多报告了多发病与血液生物标志物水平升高之间的关联。结论：本综述提示老年人群中多发病与AD血液生物标志物之间存在显著关联，而脑脊液的结果则是混合且不一致的。需要进一步的研究，特别是在同一人群中评估CSF和血液生物标志物的纵向研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Geriatric Medicine GERIATRICS & GERONTOLOGY-

CiteScore

6.70

自引率

2.60%

发文量

114

审稿时长

6-12 weeks

期刊介绍： European Geriatric Medicine is the official journal of the European Geriatric Medicine Society (EUGMS). Launched in 2010, this journal aims to publish the highest quality material, both scientific and clinical, on all aspects of Geriatric Medicine. The EUGMS is interested in the promotion of Geriatric Medicine in any setting (acute or subacute care, rehabilitation, nursing homes, primary care, fall clinics, ambulatory assessment, dementia clinics..), and also in functionality in old age, comprehensive geriatric assessment, geriatric syndromes, geriatric education, old age psychiatry, models of geriatric care in health services, and quality assurance.